239 related articles for article (PubMed ID: 22306525)
1. Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.
Loewinger GC; Beckert MV; Tejeda HA; Cheer JF
Neuropharmacology; 2012 Jun; 62(7):2192-201. PubMed ID: 22306525
[TBL] [Abstract][Full Text] [Related]
2. Endocannabinoids promote cocaine-induced impulsivity and its rapid dopaminergic correlates.
Hernandez G; Oleson EB; Gentry RN; Abbas Z; Bernstein DL; Arvanitogiannis A; Cheer JF
Biol Psychiatry; 2014 Mar; 75(6):487-98. PubMed ID: 24138924
[TBL] [Abstract][Full Text] [Related]
3. Methamphetamine-induced neurotoxicity disrupts naturally occurring phasic dopamine signaling.
Howard CD; Daberkow DP; Ramsson ES; Keefe KA; Garris PA
Eur J Neurosci; 2013 Jul; 38(1):2078-88. PubMed ID: 23574406
[TBL] [Abstract][Full Text] [Related]
4. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
[TBL] [Abstract][Full Text] [Related]
5. Effect of CB1 receptor blockade on food-reinforced responding and associated nucleus accumbens neuronal activity in rats.
Hernandez G; Cheer JF
J Neurosci; 2012 Aug; 32(33):11467-77. PubMed ID: 22895729
[TBL] [Abstract][Full Text] [Related]
6. Neural encoding of psychomotor activation in the nucleus accumbens core, but not the shell, requires cannabinoid receptor signaling.
Morra JT; Glick SD; Cheer JF
J Neurosci; 2010 Apr; 30(14):5102-7. PubMed ID: 20371830
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.
Dazzi L; Talani G; Biggio F; Utzeri C; Lallai V; Licheri V; Lutzu S; Mostallino MC; Secci PP; Biggio G; Sanna E
PLoS One; 2014; 9(3):e92224. PubMed ID: 24632810
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens.
Morra JT; Glick SD; Cheer JF
Neuropharmacology; 2012 Sep; 63(4):565-74. PubMed ID: 22609048
[TBL] [Abstract][Full Text] [Related]
9. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.
Cheer JF; Wassum KM; Sombers LA; Heien ML; Ariansen JL; Aragona BJ; Phillips PE; Wightman RM
J Neurosci; 2007 Jan; 27(4):791-5. PubMed ID: 17251418
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.
Cheer JF; Wassum KM; Heien ML; Phillips PE; Wightman RM
J Neurosci; 2004 May; 24(18):4393-400. PubMed ID: 15128853
[TBL] [Abstract][Full Text] [Related]
11. Methamphetamine-induced neurotoxicity disrupts pharmacologically evoked dopamine transients in the dorsomedial and dorsolateral striatum.
Robinson JD; Howard CD; Pastuzyn ED; Byers DL; Keefe KA; Garris PA
Neurotox Res; 2014 Aug; 26(2):152-67. PubMed ID: 24562969
[TBL] [Abstract][Full Text] [Related]
12. Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids.
Covey DP; Bunner KD; Schuweiler DR; Cheer JF; Garris PA
Eur J Neurosci; 2016 Jun; 43(12):1661-73. PubMed ID: 27038339
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala.
Alvarez-Jaimes L; Polis I; Parsons LH
Neuropsychopharmacology; 2008 Sep; 33(10):2483-93. PubMed ID: 18059440
[TBL] [Abstract][Full Text] [Related]
14. Pseudoginsenoside-F11 inhibits methamphetamine-induced behaviors by regulating dopaminergic and GABAergic neurons in the nucleus accumbens.
Fu K; Lin H; Miyamoto Y; Wu C; Yang J; Uno K; Nitta A
Psychopharmacology (Berl); 2016 Mar; 233(5):831-40. PubMed ID: 26621348
[TBL] [Abstract][Full Text] [Related]
15. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
[TBL] [Abstract][Full Text] [Related]
16. Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens.
Sperlágh B; Windisch K; Andó RD; Sylvester Vizi E
Neurochem Int; 2009 Jun; 54(7):452-7. PubMed ID: 19428788
[TBL] [Abstract][Full Text] [Related]
17. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats.
Caillé S; Parsons LH
Eur J Neurosci; 2003 Dec; 18(11):3145-9. PubMed ID: 14656311
[TBL] [Abstract][Full Text] [Related]
18. Intra-accumbens rimonabant is rewarding but induces aversion to cocaine in cocaine-treated rats, as does in vivo accumbal cannabinoid CB1 receptor silencing: critical role for glutamate receptors.
Ramiro-Fuentes S; Ortiz O; Moratalla R; Fernandez-Espejo E
Neuroscience; 2010 May; 167(2):205-15. PubMed ID: 20167255
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.
Li X; Hoffman AF; Peng XQ; Lupica CR; Gardner EL; Xi ZX
Psychopharmacology (Berl); 2009 May; 204(1):1-11. PubMed ID: 19099297
[TBL] [Abstract][Full Text] [Related]
20. Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice.
Mereu M; Tronci V; Chun LE; Thomas AM; Green JL; Katz JL; Tanda G
Addict Biol; 2015 Jan; 20(1):91-103. PubMed ID: 23910902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
